Trial Profile
A prospective, single centre trial to evaluate the safety and efficacy of enzalutamide (Xtandi ®) in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel plus prednisone
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Mar 2017
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 27 Mar 2017 New trial record
- 01 Mar 2017 Primary endpoint has been met. (reduction in serum prostate-specific antigen (PSA)) as per results published in the Anticancer Research.
- 01 Mar 2017 Results published in the Anticancer Research